← Back to Search

Other

Gemfibrozil effet on camlipixant pharmacokinetics for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bellus Health Inc. - a GSK company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre dose to up to 72 hours post-dose

Awards & highlights

Study Summary

This trial tests how safe a drug is by studying how it interacts with existing drugs in healthy people.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre dose to up to 72 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre dose to up to 72 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre dose to up to 72 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Measurement of the area under the plasma concentration by time curve (AUC0-inf)

Measurement of the area under the plasma concentration by time curve (AUC0-t)

Measurement of the maximum observed plasma drug concentration (Cmax)

Trial Design

2Treatment groups

Experimental Treatment

Group I: Gemfibrozil effet on camlipixant pharmacokineticsExperimental Treatment1 Intervention

Group II: Camlipixant effect on dabigatran etexilate pharmacokineticsExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Camlipixant + Gemfibrozil

2023

Completed Phase 1

~40

Dabigatran etexilate + camlipixant

2023

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bellus Health Inc. - a GSK companyLead Sponsor

17 Previous Clinical Trials

5,306 Total Patients Enrolled

Bellus Health IncLead Sponsor

15 Previous Clinical Trials

5,240 Total Patients Enrolled

Media Library

Camlipixant + Gemfibrozil (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05959447 — Phase 1

Healthy Subjects Research Study Groups: Gemfibrozil effet on camlipixant pharmacokinetics, Camlipixant effect on dabigatran etexilate pharmacokinetics

Healthy Subjects Clinical Trial 2023: Camlipixant + Gemfibrozil Highlights & Side Effects. Trial Name: NCT05959447 — Phase 1

Camlipixant + Gemfibrozil (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05959447 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who is allowed to join in this trial's proceedings?

"To qualify for this research, participants must be within the age range of 18 to 55 years old and in good health. 36 people are needed for this clinical trial."

Answered by AI

Does this trial include individuals who are in their forties or older?

"For this trial, only individuals aged between 18 and 55 can be included. However, there are 56 studies open to minors while 376 trials have been made available for senior citizens."

Answered by AI

Are there still open slots for volunteers in this research endeavor?

"As per the data on clinicaltrials.gov, this trial is not currently enrolling participants. The study was initially announced on August 1st 2023 and its details were last updated 17th July of that same year. Even though recruitment for this particular investigation has been halted, 805 other medical trials are actively seeking patient enrolment at present."

Answered by AI

Has the FDA sanctioned any research demonstrating how Gemfibrozil influences camlipixant pharmacokinetics?

"Our team at Power has assigned the safety of gemfibrozil's effect on camlipixant pharmacokinetics a score of 1 because this is an initial stage trial and there is minimal data to support its efficacy or safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant

2023. "Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05959447.